HR955/S285, Medicaid Reentry Act; HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act; FY22 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment
HR5376, Build Back Better Act, re substance use disorder and mental health treatment
Duration: July 1, 2019
to
October 31, 2021
General Issues: Health Issues , Medicare/Medicaid
Spending: about $150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Frank J Purcell
Deputy chief of staff, office of Rep R Cunningham, end 6/2000
Frank Purcell
Deputy chief of staff, office of Rep R Cunningham, end 6/2000
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
CARDINAL WAYPOINT LLC terminated an engagement in which they represented Indivior, Inc. on Jan. 19, 2022.
Original Filing: 301326556.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act; HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act; FY22 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
HR5376, Build Back Better Act, re substance use disorder and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $20,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301976.xml
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment; HR955/S285, Medicaid Reentry Act; HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act; FY22 Labor-HHS-Education and Commerce-Justice-Science Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2021
In Q2, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $20,000. The report was filed on July 16, 2021.
Original Filing: 301277293.xml
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment; HR955/S285, Medicaid Reentry Act; HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act; FY22 Labor-HHS-Education and Commerce-Justice-Science Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2021
In Q1, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $20,000. The report was filed on April 19, 2021.
Original Filing: 301258162.xml
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment; HR955/S285, Medicaid Reentry Act; HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act; FY22 Labor-HHS-Education and Commerce-Justice-Science Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
HR1319, American Rescue Plan Act re funding for SUD and mental health treatment; HR955/S285, Medicaid Reentry Act; Medicaid final rule on DUR & VBP 85 FR 87000 12/31/2020 re line extension and accumulator programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2020
In Q4, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $20,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236235.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder. HR 4712 / S 3271, Fairness in Orphan Drug Exclusivity Act. HR 1329, the Medicaid Reentry Act. HR 1865 / HR 2740, FY21 Labor-HHS-Education Appropriations Act. HR 3055, FY21 Commerce-Justice-Science Appropriations Act. HR 4378 / HR 3055, FY21 Continuing Resolution Appropriations Act. HR 133 Omnibus FY21 Appropriations and COVID Relief
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2020
In Q3, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $20,000. The report was filed on Oct. 15, 2020.
Original Filing: 301210087.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder. HR 4712 / S 3271, Fairness in Orphan Drug Exclusivity Act. HR 1329, the Medicaid Reentry Act. HR 6800 /HR 925 as amended, HEROES Act. HR 1865 / HR 2740, FY21 Labor-HHS-Education Appropriations Act, HR 3055, FY21 Commerce-Justice-Science Appropriations Act. HR 4378 / HR 3055, FY21 Continuing Resolution Appropriations Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2020
In Q2, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $10,000. The report was filed on July 20, 2020.
Original Filing: 301195696.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder. HR 4712 / S 3271, Fairness in Orphan Drug Exclusivity Act. HR 1329, the Medicaid Reentry Act. FY21 Labor-HHS-Education Appropriations Act, FY21 Commerce-Justice-Science Appropriations Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2020
In Q1, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $10,000. The report was filed on April 17, 2020.
Original Filing: 301170640.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder. HR 4712 / S 3271, Fairness in Orphan Drug Exclusivity Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2019
In Q4, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $10,000. The report was filed on Jan. 20, 2020.
Original Filing: 301121997.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, CARDINAL WAYPOINT LLC lobbied for Indivior, Inc. , earning $10,000. The report was filed on Oct. 21, 2019.
Original Filing: 301073321.xml
Lobbying Issues
Expand access to treatment for persons with opioid use disorder.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Expand access to treatment for persons with opioid use disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
CARDINAL WAYPOINT LLC filed a lobbying registration on July 3, 2019 to represent Indivior, Inc., effective July 1, 2019.
Original Filing: 301043128.xml
Issue(s) they said they’d lobby about: Patient access to all FDA-approved medications and formulations for treatment of OUD .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate